Exploring the Management of Pediatric Relapsed/Refractory Acute Leukemia - Episode 4

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

May 22, 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Current Treatment Strategies in Pediatric R/R AML and ALL

EP. 2: Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

EP. 3: When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

Now Viewing

EP. 4: Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

EP. 5: Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

EP. 6: Factors to Consider in Pediatric Acute Leukemia Management

EP. 7: Treatment Trends and Ongoing Research in Pediatric Acute Leukemia